Mineralys Therapeutics (MLYS) Net Cash Flow (2022 - 2026)

Mineralys Therapeutics has reported Net Cash Flow for 5 years, with the latest figure at -$60.1 million in Q1 2026.

• Quarterly Net Cash Flow fell 218.12% year-over-year to -$60.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$52.2 million (down 170.02% YoY) and the FY2025 annual result came in at $58.8 million, down 9.19% from the prior year.
• Net Cash Flow eased to -$60.1 million in Q1 2026 per MLYS's latest filing, from -$44.7 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $115.9 million in Q3 2025 and troughed at -$79.3 million in Q3 2022.
• A 5-year average of $6.0 million and a median of $5.4 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow jumped 832.74% in 2023, then plunged 365.83% in 2025.
• Over 5 years, Net Cash Flow stood at $38.7 million in 2022, then sank by 195.48% to -$37.0 million in 2023, then surged by 145.46% to $16.8 million in 2024, then slumped by 365.83% to -$44.7 million in 2025, then plunged by 34.53% to -$60.1 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$60.1 million, -$44.7 million, and $115.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.